PREVIEW ASH 2026 — New Orleans, Dec 12–15: the abstracts hematologists are watching, top voices and trial buzz See the ASH 2026 preview →
KOL Pulse · ESMO 2026 · Madrid · Oct 23–27 · Results

ESMO 2026 Slide Library

ESMO 2026 trial results & KOL discussion, by trial →

Results slides from ESMO 2026 (Madrid, October 23–27), posted since the October 22 embargo lift: 1732 slide posts and 368 KOL infographics from 378 accounts, now on one page per tumor type, each organized by clinical trial with verbatim OCR text, trial and KOL filters, and links to KOL Pulse trial pages. Updated October 29, 2026. ← Back to the full ESMO 2026 coverage

Pick a tumor type to open its slides. Pre-congress previews, watchlists and top-10 lists are in the pre-congress slide archive →
ESMO 2026 trial results & KOL discussions, by trial →Each slide group below also links to its Full trial page and All posts.

KOL Pulse trial pages for ESMO 2026 trials 59

Trials in this slide library that have a full KOL Pulse trial page (data, sources and KOL voices). Every ESMO 2026 post grouped by trial is on the ESMO 2026 trial results page →

Choose a tumor type

ADC slides: Breast Cancer 165 · Lung Cancer 125 · GU Cancer 149 · GI Cancer 44 · Melanoma 3 · Gyn Cancer 27 · Heme & Other 36 (antibody-drug conjugate slides; opens the tumor page with the ADC filter on)

Lung Cancer slides →

420 slide posts · 91 KOL infographics · 27 trials with slide groups · 441 of 511 posts from physicians
DeLLphi-305, KRASCENDO-1 ESMO 2026 slide — Kaplan-Meier survival data: NEJM ESMO article card: osimertinib plus (1 of 4) (shared by Adam C Palmer)DeLLphi-305 ESMO 2026 slide — Kaplan-Meier survival data: OS Kaplan-Meier curve, tarlatamab + durvalumab vs durvalumab (shared by Enes Erul MD)KRASCENDO-1 ESMO 2026 slide: Besse invited discussion LBA5: KRAS G12C inhibitor drug access map — Presidential Symposium II (shared by Yakup Ergün)ESMO 2026 slide — Kaplan-Meier survival data: HARMONi-GI1: OS primary endpoint, ivonescimab + chemo vs durvalumab + chemo (shared by ツチノコ在宅ケモ屋)

GU Cancer slides →

453 slide posts · 61 KOL infographics · 18 trials with slide groups · 374 of 514 posts from physicians
PROTEUS ESMO 2026 slide — trial design schema: substudy design: perioperative apalutamide + ADT with RP+PLND (1 of 4) (shared by Zach Klaassen)DASL-HiCaP ESMO 2026 slide — trial design schema: study design (Niazi, ESMO 2026) (1 of 3) (shared by Shankar Siva)KEYNOTE-B15 / EV-304, KEYNOTE-866 ESMO 2026 slide: Cross-trial comparison table of perioperative IO in MIBC: ENERGYZE, KN866 (shared by Tom Powles)JNJ-6143 Phase 1 ESMO 2026 slide: JNJ-6143 (RIPTAC) phase 1 mCRPC/mAPMR title slide and author list (1 of 4) (shared by Andy Hahn)

GI Cancer slides →

254 slide posts · 62 KOL infographics · 27 trials with slide groups · 280 of 316 posts from physicians
ESMO 2026 slide — Kaplan-Meier survival data: NICHE-2 Kaplan-Meier curve, neoadjuvant ipilimumab + nivolumab in dMMR (shared by Nicholas Hornstein)ESMO 2026 slide — biomarker data: 1975P poster: HCB301-101 phase 1 of tri-functional SIRPα/PD-L1/TGF-β biologic in advanced (shared by Samuel Hume)ESMO 2026 slide — biomarker data: AMPLIFY-7P camupepimut pre-specified DFS by ctDNA status (O'Reilly) (shared by Samuel Hume)PRABITAS ESMO 2026 slide — trial design schema: study design (Taniguchi, ESMO 2026) (1 of 4) (shared by Nieves Martinez Lago MD PhD)

Melanoma slides →

62 slide posts · 27 KOL infographics · 2 trials with slide groups · 73 of 89 posts from physicians
INTerpath-001 ESMO 2026 slide: Photo/screenshot of presented ESMO 2026 conference slide (shared by Yakup Ergün)INTerpath-001 ESMO 2026 slide: Photo of presented slide on stage screen (shared by Professor Georgina Long AO (Bluesky @gvlongphdmd))INTerpath-001 ESMO 2026 slide: LBA1 abstract screenshot (Long, ESMO 2026) (shared by Yakup Ergün)INTerpath-001 ESMO 2026 slide — Kaplan-Meier survival data: Recurrence-Free Survival, ITT population (Long, ESMO 2026 LBA1) (shared by ツチノコ在宅ケモ屋)
Built byMario Balsa18Yago Garitaonaindía6MV Chandrakanth4Mustafa Özdoğan, MD4Yakup Ergün2Alfredo Addeo MD2Prof. Dr. Ahmet Dirican2Professor Georgina Long AO (Bluesky @gvlongphdmd)1

Gyn Cancer slides →

35 slide posts · 25 KOL infographics · 10 trials with slide groups · 47 of 60 posts from physicians
ESMO 2026 slide — response data: Efficacy of elfe-D plus pumitamig (shared by Samuel Hume)DUO-E ESMO 2026 slide — Kaplan-Meier survival data: interim OS Kaplan-Meier curve, dMMR subpopulation (1 of 4) (shared by Aya Mohamed | MSc, MD 🎗)TroFuse-005 ESMO 2026 slide — Kaplan-Meier survival data: progression-free survival by BICR: sacituzumab tirumotecan (1 of 4) (shared by DrKatyMoore)DUO-E, NRG-GY020 ESMO 2026 slide: GY020 / B21 / verdicts summary table (1 of 4) (shared by Dr Amol Akhade)
Built byDrKatyMoore16Dr Amol Akhade5JOSE ALEJANDRO PEREZ FIDAL4MV Chandrakanth2Mali Barbi, MD MSc | Breast & Gyn Oncologist2Mustafa Özdoğan, MD2Nirmal Raut2Christi Kim2

Heme & Other slides →

214 slide posts · 54 KOL infographics · 5 trials with slide groups · 208 of 268 posts from physicians
ESMO 2026 slide — Kaplan-Meier survival data: Ris-Rez (risvutatug rezetecan) vs gemcitabine + docetaxel: primary (shared by Roberto Pestana, MD, PhD)MOIO ESMO 2026 slide: (LBA10) abstract: reduced-frequency immune checkpoint inhibitors in responding patients (1 of 4) (shared by Dr Amol Akhade)ESMO 2026 slide: Total control of nausea and vomiting: mirtazapine (FDP-M) vs olanzapine (FDP-O) (1 of 2) (shared by Nicholas Hornstein)ESMO 2026 slide — Kaplan-Meier survival data: Overall survival KM curve, ribociclib + NSAI vs NSAI alone (shared by Michiel Strijbos)
Built byNieves Martinez Lago MD PhD12Jeff Ryckman12Herbert Loong, MBBS, FASCO7Dr Amol Akhade6Mario Balsa6Evelyn Wong6Pablo Jiménez5Dario Trapani5
Free Access · KOL Pulse Intelligence

Track oncology’s top KOLs in your specialty

Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:

  • ✓Enhanced KOL profiles
  • ✓Pharma influence & potential advisory-board patterns
  • ✓2025 Open Payments financial analysis
  • ✓Social-media sentiment & trend signals
Get free access — pick your specialty
Choose the tumor types you follow. No cost, unsubscribe anytime.

KOL infographics by tumor type

Summary graphics physicians, media and companies designed themselves sit in a compact section at the end of each tumor page: Breast Cancer 48 · Lung Cancer 91 · GU Cancer 61 · GI Cancer 62 · Melanoma 27 · Gyn Cancer 25 · Heme & Other 54.

About this slide library

What is the ESMO 2026 slide library?

A gallery of the 1732 results slide posts and 368 KOL-made infographics that oncologists, societies, media and companies posted on X from the ESMO 2026 embargo lift (October 22) through the congress in Madrid (October 23–27), compiled by KOL Pulse. It is split into one page per tumor type so each page loads quickly on a phone; every card keeps the author's full text, a link to the original post and a verbatim OCR transcription of the slide.

Which tumor-type pages are there?

Breast Cancer (294 slide posts): https://kolpulse.com/kol-pulse-esmo26-slides-breast; Lung Cancer (420 slide posts): https://kolpulse.com/kol-pulse-esmo26-slides-lung; GU Cancer (453 slide posts): https://kolpulse.com/kol-pulse-esmo26-slides-gu; GI Cancer (254 slide posts): https://kolpulse.com/kol-pulse-esmo26-slides-gi; Melanoma (62 slide posts): https://kolpulse.com/kol-pulse-esmo26-slides-melanoma; Gyn Cancer (35 slide posts): https://kolpulse.com/kol-pulse-esmo26-slides-gyn; Heme & Other (214 slide posts): https://kolpulse.com/kol-pulse-esmo26-slides-other.

How are the tumor pages organized?

Each page groups slides by clinical trial, with links to the trial's KOL Pulse trial page and its discussion on the ESMO 2026 conference page. Cross-trial comparisons and slides not tied to a tracked trial come last, physician posts come first, and KOL-made infographics sit in a compact section after the slides. Filters by trial and KOL are on every page.

Where are the pre-congress previews and watchlists?

Everything posted before the October 22 embargo lift, including previews, watchlists and top-10 lists, is in the ESMO 2026 pre-congress slide archive: https://kolpulse.com/kol-pulse-esmo26-slides-archive

Can I use these pages with my own AI assistant (NotebookLM, Perplexity, Claude, ChatGPT)?

Yes. Paste a tumor page URL, or a filtered link, into your assistant and ask questions against it. Example prompt: "From the slide transcriptions on this page, list each trial's primary endpoint result with the hazard ratio and data cut exactly as printed on the slide, and the physician who posted it."

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated October 29, 2026. Every card links to its original post; slide text is a verbatim transcription.